734 related articles for article (PubMed ID: 27170387)
21. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases
Nevens F; Trauner M; Manns MP
J Hepatol; 2023 Feb; 78(2):430-441. PubMed ID: 36272496
[TBL] [Abstract][Full Text] [Related]
22. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
23. Obeticholic acid in primary biliary cholangitis: where we stand.
Manne V; Kowdley KV
Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
[TBL] [Abstract][Full Text] [Related]
24. Primary biliary cholangitis: Old and novel therapy.
Floreani A; Mangini C
Eur J Intern Med; 2018 Jan; 47():1-5. PubMed ID: 28669591
[TBL] [Abstract][Full Text] [Related]
25. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
Wong LL; Hegade VS; Jones DEJ
Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
[TBL] [Abstract][Full Text] [Related]
26. Current pharmacotherapy for cholestatic liver disease.
Carey EJ; Lindor KD
Expert Opin Pharmacother; 2012 Dec; 13(17):2473-84. PubMed ID: 23094715
[TBL] [Abstract][Full Text] [Related]
27. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
28. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Bowlus CL; Kenney JT; Rice G; Navarro R
J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
[TBL] [Abstract][Full Text] [Related]
29. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
30. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
[TBL] [Abstract][Full Text] [Related]
31. Current Treatment Options for Primary Biliary Cholangitis.
Wong KA; Bahar R; Liu CH; Bowlus CL
Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848
[TBL] [Abstract][Full Text] [Related]
32. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
33. Farnesoid X receptor agonists for primary biliary cirrhosis.
Lindor KD
Curr Opin Gastroenterol; 2011 May; 27(3):285-8. PubMed ID: 21297469
[TBL] [Abstract][Full Text] [Related]
34. Obeticholic acid for the treatment of primary biliary cirrhosis.
Trivedi PJ; Hirschfield GM; Gershwin ME
Expert Rev Clin Pharmacol; 2016; 9(1):13-26. PubMed ID: 26549695
[TBL] [Abstract][Full Text] [Related]
35. Chronic cholestatic diseases.
Poupon R; Chazouillères O; Poupon RE
J Hepatol; 2000; 32(1 Suppl):129-40. PubMed ID: 10728800
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
37. Primary biliary cholangitis: pathogenesis and therapeutic opportunities.
Gulamhusein AF; Hirschfield GM
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):93-110. PubMed ID: 31819247
[TBL] [Abstract][Full Text] [Related]
38. [New name and new treatments for primary biliary cholangitits].
Bossen L; Ytting H; Jepsen P; Hamberg O; Ott P; Grønbæk H
Ugeskr Laeger; 2018 Mar; 180(10):. PubMed ID: 29536837
[TBL] [Abstract][Full Text] [Related]
39. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
Ahn DW
Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856
[TBL] [Abstract][Full Text] [Related]
40. Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.
Kasztelan-Szczerbinska B; Rycyk-Bojarzynska A; Szczerbinska A; Cichoz-Lach H
Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
